ArticleRadiology2026
Noninvasive Differentiation of Indolent from Aggressive Renal Neoplasms with MR Fingerprinting Combined with Diffusion/Perfusion MRI.
Article in Radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background Accurate characterization of tumor grade and aggressiveness for renal neoplasms with noninvasive imaging methods is critical for patient management and outcome. Purpose To evaluate kidney MR fingerprinting (MRF) alone and in combination with diffusion-weighted imaging and arterial spin labeling (ASL) MRI for the diagnosis and characterization of renal neoplasms by assessing its performance in differentiating indolent from aggressive tumors. Materials and Methods Adults with suspected renal cell carcinoma (RCC) were recruited between November 2020 and October 2024 for this prospective proof-of-concept study. Histopathologic grading served as the reference standard, and renal masses were classified into indolent (low-grade or benign) and aggressive (high-grade or unclassified RCCs) types according to their natural biologic behavior. Noncontrast coronal T1 and T2 maps were acquired using breath-hold kidney MRF (two to five sections per participant) at 3.0 T. Respiratory-triggered diffusion-weighted imaging and ASL MRI were further applied to measure the apparent diffusion coefficient (ADC) and renal blood flow (RBF), respectively. Univariable and multivariable analyses were performed to identify parameters that differentiated renal neoplasms and correlated with histopathologic findings. Results Renal neoplasms from 24 participants (mean age, 61 years ± 11 [SD]; 16 female) were characterized as indolent (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.